Table 1.
Summary of studies describing the use of chemotherapy in aGCT.
| Author, Year | Study Design | Study Period | Patients (n) |
Stage at Diagnosis | Previous Treatment n (%) |
Chemotherapy n (%) |
Response n (%) |
PFS (mo) Median (Range) |
OS (mo) Median (Range) |
FU (mo) Median (Range) |
Disease Status n (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tresukosol, 1995 [34] | retrospective case report | 1992–1994 | 1 | IC 1 | S ×1, CT ×1 | paclitaxel 1(100) | PR 1 (100) | 12 | 24+ 1 | 24 1 | AWD 1 (100) 1 |
| Shavit, 2012 [35] | retrospective case report | 2006–2007 | 1 | IA | S ×2, CT ×2 | docetaxel 1 (100) | SD 1 (100) | 24 | NA | 24 | NA |
| Uygun, 2003 [36] | retrospective cohort | 1979–1999 | 4 | IIIB-IV | S 4 (100) CT 4 (100) |
CC 3 (75) CAP 1 (25) |
CR 2 (50) PR 2 (50) |
38 (21–73) 1 | 40.5 (33–73) 1 | 40.5 (33–73) 1 | NED 2 (50) DOD 1 (25) DOC 1 (25) |
| Pectasides, 2008 [37] | retrospective cohort | 1983–2007 | 5 | IA-IV | S 5 (100) CT 5 (100) |
CP 2 (40) CVB 1 (10) 5FU 2 (40) |
CR 2 (40) PR 1 (20) PD 2 (40) |
7 (0–31) 1 | 28 (4–31) 1 | NA | AWD 4 (80) DOD 1 (20) |
| van Meurs, 2014 [16] | retrospective cohort | 1968–2011 | 9 | I-IIIC | S 9 (100) RT 1 (11) AHT 1 (11) |
BEP 9 (100) | CR 1 (11) PR 1 (11) SD 7 (78) |
12 (2–50) | 50 (4–165) | NA | NED 2 (22) AWD 3 (33) DOD 3 (33) DOC 1 (11) |
| Wilson, 2015 [30] | retrospective cohort | 1955–2012 | 17 2 | IA-IC | S 17 (100) CT ns, RT ns | CT 17 (100) | CR 1 (3) PR 8 (27) SD 4 (13) PD 15 (50) ×1 3 |
8.6 | NA | NA | NA |
| Brown, 2004 [11] | retrospective cohort | 1985–2002 | 21aGCT /30SCST |
IA-IIIC | S 30 (100) CT 22 (73) RT 2 (7) |
NPT 17 (57) PT 13 (43) |
CR 3 (10) PR 7 (23) SD 7 (23) PD 12 (40) 4 |
16.8 (0–68) | NA | 100.7 (8.1–361.3) | NED 3 (10) AWD 20 (67) DOD 5 (17) DOC 2 (6) |
| Pautier, 2008 [13] | prospective cohort | 1990–2002 | 14aGCT /20GCT |
I-IV | S 20 (100) CT 1 (5) | BEP 20 (100) | CR 9 (45) PR 9 (45) SD 1 (5) PD 1 (5) |
24 (4–84) | 46 | 45 (3–112) | NED 9 (45) AWD 3 (15) DOD 8 (40) |
| Burton, 2016 [31] | prospective cohort | 2000–2013 | 31 SCST | NA | S 31 (100) CT 24 (77) RT 3 (10) AHT 3 (10) IT 1 (3) |
paclitaxel 31 (100) | CR 1(3) PR 8 (26) SD 15 (48) PD 6 (19) 5 |
10 | 73.6 | 67 | AWD 15 (48) DOD 16 (52) |
| Ray-Coquard, 2020 [32] | prospective RCT | 2013–2020 | 27aGCT /32 SCST |
I-IV | S 32 (100) CT 32 (100) RT 4 (13) AHT 8 (25) |
paclitaxel 32 (100) | CR 0 (0) PR 8 (25) SD 17 (53) PD 7 (22) |
14.7 (95% CI 11.5–18.3) | NA | 38.9 (IQR 36.4–43.8) |
AWD 26 (81) DOD 6 (19) |
1 Calculated by authors of this paper; 2 30 regimens; 3 two patients did not have response recorded; 4 one patient who died as a result of unrelated medical causes whose response could not be assessed; 5 one patient (3%) was indeterminate; PFS: progression-free survival, OS: overall survival, FU: follow-up in time, RCT: randomized controlled trial, NA: not available, ns: not specified; response according to RECIST criteria: CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease; disease status: NED: no evidence of disease, AWD: alive with disease, DOD: death of disease, DOC: death of other cause; treatments: 5FU: 5-fluorouracil, AHT: anti-hormonal therapy, BEP: bleomycin-etoposide-cisplatin, CAP: cyclophosphamide-doxorubicin-cisplatin, CC: cyclophosphamide-cisplatin; CP: carboplatin-paclitaxel, CT: chemotherapy, CVB: cisplatin-vinblastine-bleomycin, IT: immunotherapy, NPT: non–platinum containing taxane regimens, PT: platinum-containing taxane regimens, RT: radiotherapy, S: surgery.